Pyxis Oncology (PYXS)
NASDAQ:PYXS
Want to see PYXS full AI Analyst Report?
PYXS Stock Chart & Stats
$1.66
-$0.10(-5.75%)
At close: 4:00 PM EST
$1.66
-$0.10(-5.75%)
Day’s Range― - ―
52-Week Range$0.97 - $5.55
Previous CloseN/A
Volume258.73K
Average Volume (3M)757.02K
Market Cap
$108.34M
Enterprise Value$125.06M
Total Cash (Recent Filing)$42.49M
Total Debt (Recent Filing)$18.26M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 19, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding63,355,480
10 Day Avg. Volume789,983
30 Day Avg. Volume757,017
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.34
Price to Sales (P/S)5.16
P/FCF Ratio-1.13
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue9.02
Enterprise Value/Gross Profit9.04
Enterprise Value/Ebitda-1.56
Forecast
1Y Price Target
$6.50Price Target Upside291.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.24
Revenue Forecast (FY)$50.00K
Bulls Say, Bears Say
Bulls Say
Regulatory Alignment For Pivotal TrialObtaining FDA alignment on pivotal trial design materially lowers regulatory execution risk and clarifies endpoints and pathways to approval. This durable development-focused milestone improves program predictability, aids partner discussions, and supports a clear clinical development timeline over the next 2–6 months and beyond.
Completed Enrollment And Scheduled ReadoutsTarget enrollment completion and proximate data readouts de-risk program timelines and concentrate near-term catalysts into defined windows. Reliable trial execution and upcoming efficacy/safety data strengthen the case for partnership, licensing, or accelerated development decisions, sustaining strategic options for months ahead.
Operational Strengthening And Extended RunwayExtending runway reduces immediate financing pressure while experienced leadership and senior clinical/IR hires bolster execution capabilities. Improved management and operational depth increase the company’s ability to navigate regulatory interactions, execute trials, and engage partners over a multi-quarter horizon.
Bears Say
Persistent Heavy Cash BurnSustained negative operating and free cash flow at this magnitude creates a structural funding need that will persist absent commercialization. Over the medium term this forces reliance on external financing, increasing dilution risk and potentially constraining trial scope or timing if capital markets deteriorate.
Eroding Equity Base And Shrinking AssetsSharp contraction in equity and assets reduces the company’s financial cushion and flexibility. A diminished balance sheet heightens vulnerability to adverse trial outcomes or funding delays, limiting the firm’s ability to self-fund pivotal studies and elevating the probability of dilutive capital raises.
No Commercial Revenue; Development-stage Funding ModelOperating as a pre-revenue biotech means the firm lacks recurring sales to sustain operations, relying on milestone/license events or financing. This structural revenue absence keeps the company dependent on capital markets and partners until approvals, affecting durability of funding and long-term independence.
Pyxis Oncology News
PYXS FAQ
What was Pyxis Oncology’s price range in the past 12 months?
Pyxis Oncology lowest stock price was $0.97 and its highest was $5.55 in the past 12 months.
What is Pyxis Oncology’s market cap?
Pyxis Oncology’s market cap is $108.34M.
When is Pyxis Oncology’s upcoming earnings report date?
Pyxis Oncology’s upcoming earnings report date is Aug 19, 2026 which is in 77 days.
How were Pyxis Oncology’s earnings last quarter?
Pyxis Oncology released its earnings results on May 14, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.364 by -$0.006.
Is Pyxis Oncology overvalued?
According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued.
Does Pyxis Oncology pay dividends?
Pyxis Oncology does not currently pay dividends.
What is Pyxis Oncology’s EPS estimate?
Pyxis Oncology’s EPS estimate is -0.35.
How many shares outstanding does Pyxis Oncology have?
Pyxis Oncology has 63,355,480 shares outstanding.
What happened to Pyxis Oncology’s price movement after its last earnings report?
Pyxis Oncology reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.364. Following the earnings report the stock price went down -15.649%.
Which hedge fund is a major shareholder of Pyxis Oncology?
Currently, no hedge funds are holding shares in PYXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pyxis Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.50 (291.57% Upside)
$6.50 (291.57% Upside)
Hedge Fund Trend
Decreased
By 161.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 13.2%
Last 30 Days ▲ 13.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.23%
12-Months-Change
Fundamentals
Return on Equity
-135.60%
Trailing 12-Months
Asset Growth
-52.67%
Trailing 12-Months
Company Description
Pyxis Oncology
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
PYXS Stock 12 Month Forecast
Average Price Target
$6.50
▲(291.57% Upside)
Technical Analysis
Nkarta
―
Greenwich LifeSciences
―
Elicio Therapeutics
―
Biomea Fusion
―
Nuvectis Pharma
―
Ownership Overview
2.81% Insiders
4.05% Mutual Funds
31.69% Other Institutional Investors
57.41% Public Companies and Individual Investors